article thumbnail

ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology

Pharmaceutical Technology

In an exclusive interview, the CEO of ImmunoPrecise Antibodies described the benefits of rabbit monoclonal antibodies in oncology.

Antibody 130
article thumbnail

AstraZeneca and Nona Biosciences sign agreement for monoclonal antibody

Pharmaceutical Technology

AstraZeneca has entered into a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody.

Antibody 288
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer

Pharmaceutical Technology

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer and evaluation agreement (MTEA) with Biotheus on bispecific antibodies to treat cancer.

Antibody 130
article thumbnail

J&J antibody drug combination shows promise in multiple myeloma

Bio Pharma Dive

A pair of dual-acting antibodies displayed early potential to become a new type of drug regimen for the blood cancer, but led to a high rate of side effects as well.

Antibody 357
article thumbnail

Almirall licenses IL-21 antibody from Novo Nordisk

Pharmaceutical Technology

Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.

Licensing 241
article thumbnail

Talem and Libera Bio partner for discovery of AI-driven antibodies

Pharmaceutical Technology

Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.

Antibody 262
article thumbnail

Japan grants patent for BioArctic’s Parkinson’s disease antibody

Pharmaceutical Technology

Japan has granted a new drug substance patent for BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.

Antibody 245